Connect with us

Press Release

China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023

Published

5 months ago

on

CMS enters the “New Product Era” driven by exclusive and innovative products, with exclusive and innovative drugs revenue accounts for over 56%.

 

SHENZHEN, CHINA – On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. In the case that all medicines were directly sold by the Company, the turnover was RMB4,287.5 million, representing a decrease of 22.6% compared with 1H 2023, an increase of 8.9% compared with 2H 2023; Among which, the total revenue of non-National VBP exclusive products and innovative products was RMB2,404.7 million, accounting for 56.1% of CMS’s revenue in the case that all medicines were directly sold by the Company. Profit for the period was RMB903.4 million, representing a decrease of 52.8% compared with 1H 2023, a substantial increase of 92.8% compared with 2H 2023.

 

The year 2024, not only marks the first year of the commercialization of CMS’s innovative products, but also a crucial point for the release of National Volume Based Procurement (“National VBP”) impact on its financial performance. Deanxit entered the seventh batch of National VBP in November 2022, Plendil and Ursofalk entered the eighth batch of National VBP in July 2023, and none of the three original drugs were selected, which had a negative impact on the Company’s business performance. In 1H 2024, the Company’s overall performance showed a growth trend compared with 2H 2023, indicating that CMS has basically digested the impact of National VBP and successfully entered the “New Product Era” where non-national VBP exclusive products and innovative products drive its growth.

 

With the approval for marketing of LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) in June and METOJECT (Methotrexate Injection)’s additional indication of active rheumatoid arthritis (RA) in adults in July this year, CMS’s innovative drug portfolio in the commercialization stage has expanded into 5 products (including 6 indications); simultaneously with a rich and differentiated innovative pipeline reserve. Gathering the power of innovation and riding the momentum of development, CMS is comprehensively shaping new drivers for development with a healthier product structure, further opening up a new cycle of quality development.

 

The “Collaborative and In-house” dual-engine R&D model drives the simultaneous improvement in quantity and quality of the pipeline, accelerating the transformation of innovative biotechnology

 

A profound innovative drug R&D pipeline is an important driving force for the long-term development of CMS. The Company adheres to the purpose of innovation for meeting the unmet clinical needs and solving the difficulties of patient medication, and promotes innovation development through a two-wheel drive of “Collaborative R&D and In-house R&D”, continuously deploying FIC (first-in-class) and BIC (best-in-class) innovative products, and enhancing the capabilities and efficiency of research and clinical development to achieve a rapid transformation of scientific outcomes into social and commercial values.

 

As of now, CMS’s innovative product portfolio approved for marketing in China has been expanded into 5 products (including 6 indications), among which, 4 innovative drugs (VALTOCO, ILUMETRI, METOJECT – psoriasis indication, VELPHORO) have been included in the National Reimbursement Drug List (NRDL) and entered large-scale clinical application; also, CMS newly added LUMEBLUE and METOJECT (RA), for being approved for marketing in China recently.

 

CMS has also steadily advanced the clinical development of innovative products. Currently, Desidustat Tablets is under NDA review in China; Also, a total of about 10 projects have been prepared/launched for their registrational clinical trials, mainly randomized controlled trials (RCT).

 

At the same time, the Company had continued to strengthen basic research and independent innovation capabilities, and successfully promoted more than 10 in-house R&D projects, among which, three innovative drugs (VEGFA/ANG2 Tetravalent Bispecific Antibody, Highly Selective TYK2 Inhibitor CMS-D001 Tablets, and GnRH Receptor Antagonist CMS-D002 Capsules) have entered the clinical development stage.

 

In addition, the Company’s innovative pipeline has continued to expand. CMS Skinhealth collaborated with Incyte once again, and has obtained exclusive license to research, develop, register and commercialize povorcitinib, a selective oral small-molecule JAK1 inhibitor, in countries/territories including Mainland China, Hong Kong, Macau, Taiwan Region and 11 Southeast Asian countries. This further enriched the product portfolio of CMS Skinhealth in the treatment of vitiligo and other immune-mediated dermatology diseases.

 

Subsequently, CMS will continue to produce innovative products with higher efficiency and more controllable costs every year, accelerating the release of innovative value and embracing quality and sustainable performance growth through a healthy product structure dominated by non-National VBP exclusive products and innovative products.

 

Successful commercialization system releases the clinical value of innovative products in an efficient and collaborative manner

 

After 32 years of deep cultivation in specialty therapeutical fields, successful commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, it has achieved in-depth development of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology, and ophthalmology, and expanded its boundaries in related fields. Additionally, the Company established a highly qualified, professional promotion team with strong execution, as well as extensive channel and resource coverage, which has laid a solid foundation for the rapid market entry and brand building of its innovative products.

 

Four innovative drugs of CMS have entered large-scale clinical applications, covering various disease fields such as central nervous system, dermatology, nephrology, and gastroenterology, and developed synergistically with the existing marketed products in promotion team and channels. Meanwhile, leveraging on the opportunity of being included in the NRDL, CMS is advancing hospital development, brand building, real world studies and medically-driven academic promotion. CMS is improving patients’ accessibility to innovative drugs with the help of patient aid and disease knowledge popularization programs, promoting the release of products’ clinical value.

 

The Dermatology and Medical Aesthetic Business “CMS Skinhealth” regards dermatology prescription products as its core, and extends to light medical aesthetic products and dermatology-grade skincare products, continuously improving the construction of a full life-cycle skin-health management platform covering dermatological treatment, skincare, and medical aesthetics through internal development and external collaboration. In terms of clinical development of dermatology prescription drugs, CMS has completed the Pivotal Real World Study for ruxolibinib cream in vitiligo, and is advancing the registration application process in Mainland China. At the same time, it has continuously complemented the regenerative light medical aesthetic portfolio, among which the China’s medical device registration application of the Poly-L-lactic Acid Microparticle Filler Injection has been accepted by the NMPA during the Reporting Period; and the Company has newly obtained exclusive licenses of three regenerative light medical aesthetic products (Polycaprolactone Microsphere Gel for Injection, Calcium Hydroxylapatite Microsphere Gel for Injection, and Decellularized Extracellular Matrix Implant), which are currently under the registrational clinical trial stage in China.

 

The results announcement shows that, as of the end of June, the promotion network of CMS has covered over 55,000 hospitals and medical institutions, and approximately 280 thousand retail pharmacies in China.

 

Leveraging the accumulated advantages in cardio-cerebrovascular, gastroenterology, central nervous system, nephrology, ophthalmology, dermatology and other specialty therapeutical fields, CMS steadily releases the scale effect of its specialty businesses, and builds high competition barriers, creating broad commercial potential for its innovative products and exclusive products.

 

Drawing up the internationalization layout to gather momentum for the incremental market

 

Integrating the advantageous resources of the Company, its Southeast Asia business “Rxilient Health”, shares and expands the successful experience of CMS gained from the China market, as well as global quality products and innovative technological resources, into the Southeast Asia market. This accelerates the improvement of the platform integrating “R&D, manufacture, and commercialization” of the Southeast Asia business, empowering Chinese and global pharmaceutical companies to implement the “overseas development” strategy, and also opening up a larger space for incremental development opportunities for CMS.

 

As of the end of June, Rxilient Health has established a competitive product portfolio with more than ten differentiated products, covering therapeutic areas such as oncology, central nervous system, autoimmune, dermatology, and ophthalmology, etc. Rxilient Health is accelerating the relevant work on the market registration processes in Southeast Asian countries for innovative pipeline products, such as ruxolitinib cream, Methylthioninium Chloride Enteric-coated Sustained-release Tablets, and Diazepam Nasal Spray, etc. Furthermore, Rxilient Health collaborated with Junshi Biosciences to promote the registration process of toripalimab (anti-PD-1 monoclonal antibody) in multiple countries in Southeast Asia, aiming to benefit local cancer patients as soon as possible.

 

In December last year, the Company and Rxilient Health joined hands with Pharmaron and other partners to complete the purchase of the Singapore manufacturing plant. This year, all relevant parties have been orderly advancing a series of work for the Singapore manufacturing plant, including equipment testing, quality verification, and production quality system certification, etc., so as to accelerate the CDMO business development, and to optimize the Company’s overseas supply chain and manufacturing capabilities. The business layout will further facilitate more inter-industry cooperation between CMS and global partners in the future, thus jointly building a win-win medical innovation ecosystem with mutual benefits.

 

Conclusion

Since its establishment in 1992, CMS has followed the development pattern of the industry and has promoted three significant strategic transformations successfully with a forward-looking vision. The Company started as an agent of imported original drugs, gradually developed to control the rights of original/exclusive products, and then achieved a comprehensive innovative transformation. Each step of the transformation is in sync with the industry development trends. CMS steadily aims towards the ultimate goal, and constantly builds up its strength and resilience to persist through the industry development cycle. With the gradual release of the impact of national VBP on its financial performance, CMS has been transforming into a brand-new company. While embracing the innovation achievements in each stage, CMS is fully prepared for a sustainable and healthier development in the future.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Welcome to NeuraSwap—your gateway to decentralized AI finance (AiFi)

Published

1 hour ago

on

January 15, 2025

By

At the heart of the GPT Protocol, NeuraSwap redefines how we interact with the AI-driven economy. Our easy-to-use AiFi Hub empowers investors, creators, traders, and developers, fostering innovation and collaboration in a decentralized ecosystem.

What is NeuraSwap?

NeuraSwap is a decentralized AI finance platform, designed to unlock opportunities in the AI economy. By seamlessly integrating tokenized AI projects, agents, and data, NeuraSwap facilitates collaboration and exchange within a secure and transparent environment. As the official decentralized exchange (DEX) of GPT Protocol, NeuraSwap is a hub for:

  • Utility token staking
  • Premium launchpad access
  • Lending networks
  • NFT discovery

All of this is underpinned by our commitment to accessibility and inclusivity on a global scale.

Getting Started with NeuraSwap

Jump into the NeuraSwap ecosystem with ease:

  1. Engage with the Community: Join us on Twitter, Reddit, Discord, or Telegram to stay informed and connected.
  2. Use Our Platform: Swap between cryptocurrency AI tokens on the GPT Chain. Expansion to BNB Chain, Polygon, Ethereum, and Arbitrum is coming soon.
  3. Tokenize Your Portfolio: Add liquidity to token pairs and earn trading fees. Stake liquidity provider (LP) tokens in Yield Farms or Maximizers to grow your holdings.

NeuraSwap’s proprietary utility tokens, NEU and GPT, power the platform. NEU incentivizes liquidity, while GPT serves as the native gas token and provides governance benefits.

Upcoming Features

NeuraSwap continues to evolve, with exciting features on the horizon:

  • Staking Pools: Stake NEU or GPT tokens to earn rewards from partner projects.
  • Liquidity Bonds: Purchase bonds with LP tokens and receive discounted NEU or partner tokens over time.
  • Reserve Bonds: Use stablecoins or blue-chip tokens to secure discounted project tokens that vest gradually.

How NeuraSwap Empowers AI Crypto Projects

AI crypto projects partnering with NeuraSwap gain access to a suite of strategic benefits:

  • DEX Listing: Easily list AI tokens on our decentralized exchange.
  • Advisory Services: Leverage our expertise to enhance your project.
  • Partnership Ecosystem: Connect with our robust network of collaborators.
  • Co-Marketing: Expand your audience through targeted campaigns.
  • Treasury Diversification: Use Liquidity and Reserve Bonds to strengthen your financial foundation.

Why Choose NeuraSwap?

NeuraSwap is more than a platform—it’s a movement shaping the future of AI and blockchain technology. Our decentralized exchange ensures permissionless, anonymous, and efficient trading, fostering an inclusive marketplace for AI projects and participants. With innovative fundraising tools and cutting-edge blockchain integration via GPT Chain, NeuraSwap is poised to lead the AI token economy.

Mission, Vision, and Values

  • Mission: Empower investors, creators, and developers through a secure and open AiFi platform.
  • Vision: Drive global innovation in AI and blockchain, becoming the leading platform for collaboration and development in the AI economy.
  • Values: Inclusivity, trust, and innovation guide every aspect of our platform.

Get Involved

Discover NeuraSwap today, whether you’re a DeFi veteran or new to decentralized AI finance. Visit our “I’m New Here” section for a Quick Start Guide, or contact Support for assistance. Join the revolution in AiFi and help shape the future of the AI-driven economy.

Stay connected and up-to-date with NeuraSwap:

Welcome to NeuraSwap—where AI meets decentralized finance.

 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ONIX Exchange Leads the Wave of AI Copy Trading and Financial Innovation

Published

2 hours ago

on

January 15, 2025

By

A robot sitting in front of a computer monitor Description automatically generated

ONIX Exchange is at the forefront of integrating artificial intelligence (AI) into cryptocurrency trading, offering revolutionary copy trading solutions that empower users to achieve success in the fast-paced digital asset market. By leveraging advanced AI algorithms, ONIX Exchange provides a platform where users can replicate the strategies of top traders while benefiting from unparalleled efficiency, accuracy, and accessibility. This innovation is reshaping the trading landscape and setting a new standard for financial technology.

AI copy trading on ONIX Exchange works by allowing users to automatically mirror the trades of experienced and high-performing traders. The platform’s advanced AI algorithms analyze the market in real time, identifying successful trading patterns and strategies. Users can then choose from a curated selection of top traders whose strategies align with their financial goals and risk tolerance. Once selected, the AI algorithm ensures that the user’s portfolio replicates the chosen trader’s actions, executing trades with precision and speed.

What sets ONIX Exchange’s AI copy trading apart from traditional trading methods is its ability to minimize human error while maximizing efficiency. Traditional trading often requires a deep understanding of market trends, extensive research, and constant monitoring to make informed decisions. This process can be overwhelming for newcomers and time-consuming for seasoned investors. AI copy trading eliminates these barriers by automating the decision-making process and leveraging the expertise of successful traders. This ensures that users can participate in the market confidently, even without extensive trading knowledge or experience.

The AI algorithms used by ONIX Exchange offer several key advantages over traditional trading. First, they are capable of processing vast amounts of data in real time, identifying trends and opportunities that may be difficult or impossible for a human trader to detect. This enables faster, more accurate trading decisions, giving users a competitive edge in a volatile market. Additionally, the AI continuously learns and adapts, improving its performance over time to optimize trading strategies and enhance profitability.

Another major benefit of ONIX Exchange’s AI copy trading system is its accessibility. Traditional trading often requires significant time and effort to analyze markets and execute trades manually. ONIX’s solution allows users to engage in trading without dedicating extensive time to market analysis, making it an ideal option for both busy professionals and casual investors. By automating the trading process, ONIX ensures that users can capitalize on market opportunities around the clock, even while they are offline.

Security is also a cornerstone of ONIX Exchange’s AI copy trading platform. All transactions are executed through secure and transparent systems, backed by blockchain technology. Users retain full control over their funds, and the platform provides detailed reporting and analytics to ensure complete visibility into trading performance. This combination of transparency and security instills confidence in users, setting ONIX apart as a leader in the field of AI-powered trading.

In addition to its technological advancements, ONIX Exchange offers a user-friendly interface that simplifies the copy trading process. Users can easily browse and evaluate the performance metrics of top traders, including their profitability, risk levels, and trading history. This transparency allows users to make informed decisions when selecting traders to follow, ensuring that their chosen strategies align with their individual investment goals.

ONIX Exchange’s AI copy trading system also fosters a sense of community among its users. Experienced traders can share their strategies with a wider audience, earning rewards and recognition for their expertise. Meanwhile, less experienced users can learn from and benefit directly from the success of seasoned traders. This collaborative environment creates a win-win situation for all participants, driving engagement and innovation within the ONIX ecosystem.

By integrating AI copy trading with its robust suite of trading tools and services, ONIX Exchange is redefining the possibilities of financial technology. Its platform bridges the gap between traditional trading and modern automation, providing users with a powerful and intuitive way to participate in the cryptocurrency market. As ONIX continues to innovate and expand its offerings, it is leading the wave of AI-driven financial solutions that promise to transform the trading experience for users worldwide.

ONIX Exchange’s AI copy trading platform is more than just a tool—it is a revolutionary system designed to level the playing field in a space that has often been dominated by professional traders and institutional investors. By automating complex decision-making processes and providing access to the strategies of seasoned traders, ONIX ensures that even novice users can achieve success in the highly dynamic cryptocurrency market. This combination of accessibility and sophistication represents a significant leap forward for financial technology, empowering users with tools that were once out of reach for the average investor.

Contact name: Jason Scott 

Company name: Onix Exchange 

Website: https://on-ix.tr/

Country: USA

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Valencia Theater Seating Announces the Launch of the Ultimate Tuscany Heat and Ventilation Recliner

Published

2 hours ago

on

January 15, 2025

By

Introducing a revolutionary fusion of comfort, technology, and luxury for the ultimate movie-watching experience, the new Ultimate Tuscany Heat & Ventilation Recliner.

Dallas, United States, 13th Jan 2025, Grand Newswire – Valencia Theater Seating, a leading manufacturer of luxury home theater seating, is proud to announce the launch of the highly anticipated Tuscany Ultimate Heat & Ventilation Recliner. This state-of-the-art recliner is designed to provide the ultimate in comfort, luxury, and technology, creating a new standard in home theater seating. Combining the finest materials, innovative features, and superior craftsmanship, the Tuscany Ultimate Heat & Ventilation Recliner is set to redefine the way you experience your home theater.

Revolutionizing Comfort and Style

The Tuscany Ultimate Heat & Ventilation Recliner is meticulously crafted using the finest materials, ensuring it provides an unrivaled experience for movie lovers, gaming enthusiasts, and those looking to unwind in style. The recliner is 100% covered in Matte Super Supple Semi-Aniline Italian Nappa Leather 20000, an upgrade from the already luxurious top grain Nappa 11000 leather. The smooth, buttery matte finish exudes luxury, while the high-quality Italian tanning process adds an unmatched level of durability and elegance.

To enhance comfort further, the recliner features power lumbar support, a power headrest, and a recline function, all of which can be easily adjusted at the touch of a button. Whether you’re sitting upright or fully reclining, the Tuscany Ultimate Heat & Ventilation Recliner offers the perfect balance of support and relaxation.

Innovative Heat & Ventilation System

What truly sets the Tuscany Ultimate Heat & Ventilation Recliner apart from other seating options is its innovative ventilation system. This system ensures optimal airflow, preventing discomfort during extended periods of sitting. The combination of ventilated seats and integrated heating technology allows you to enjoy the best of both worlds. On chilly nights, activate the heating function to experience cozy warmth, while the ventilation system keeps you cool during warmer days, ensuring that the recliner adapts to your needs.

 

Valencia Tuscany Ultimate Luxury Heat & Ventilation Leather Home Theater Seating Row of 2, Onyx

Enjoy personalized comfort with adjustable heat and air ventilation, ensuring an ideal temperature for every viewing. The cooling seats provide optimal airflow, while the heated seat feature guarantees warmth during colder months.

 

With the touch of a button, users can control the seat’s temperature settings, personalizing their experience and ensuring that they remain comfortable throughout any movie or show. The Tuscany Ultimate Heat & Ventilation Recliner is designed to make sure that every moment of your home theater experience is perfect, no matter the season.

Perforated French Diamond Stitching for Breathability and Elegance

In addition to its cutting-edge heat and ventilation system, the Tuscany Ultimate Heat & Ventilation Recliner boasts perforated French diamond stitching, which not only adds visual appeal but also increases the breathability of the seating. This design allows for better airflow and reduces the build-up of heat in the seat, ensuring maximum comfort, especially during long viewing sessions. The perforated leather is carefully crafted to enhance the ergonomic support of the chair while providing a luxurious touch to the overall aesthetic.

The French diamond stitching is a hallmark of the high-end craftsmanship that Valencia Theater Seating is known for, and it reflects the brand’s dedication to both function and beauty. The meticulously stitched pattern also adds texture to the upholstery, making the recliner a true focal point in any home theater.

Enhanced Technological Features

The Tuscany Ultimate Heat & Ventilation Recliner is more than just a comfortable chair – it’s an integrated piece of technology. Equipped with a beautiful black chrome controller and cupholder, the recliner allows users to easily adjust their seat’s position, heat settings, and more, with an intuitive, easy-to-use interface. The USB-A and USB-C charging ports are conveniently placed on the armrest, allowing you to charge your devices while relaxing in your chair.

Additionally, the recliner features RGB LED lighting in seven colors, allowing you to personalize the ambiance of your home theater with a simple tap of a button. Whether you prefer a calming blue, a vibrant red, or a soft green, the lighting system allows you to set the perfect mood for your entertainment experience. The RGB lighting is also integrated into the black chrome cup holders, creating a sleek and modern aesthetic that complements the luxurious design of the recliner.

The memory function embedded in the controller is another standout feature. You can save your preferred reclining position, headrest angle, and lumbar support settings, ensuring that every time you sit down, the chair automatically adjusts to your ideal position.

Parisian Velour Lined Armrest Storage

One of the standout features of the Tuscany Ultimate Heat & Ventilation Recliner is the Parisian velour-lined armrest storage. This elegant storage solution is designed to keep your essentials close at hand without cluttering your seating area. The soft, luxurious velour interior ensures that your items are stored safely while adding an extra touch of sophistication to the design. It’s the perfect place to store your remote, smartphone, or even snacks for a night in the theater.

The armrest storage is easy to open and close, and its concealed design keeps everything organized and out of sight. It’s just one more way that Valencia Theater Seating has thought of everything to enhance your comfort and convenience.

Durable, Pet-Friendly Leather

Valencia Theater Seating understands that pets are an important part of the family, which is why the Tuscany Ultimate Heat & Ventilation Recliner is crafted with specially treated leather designed to resist pet scratches. Thanks to Valencia’s exclusive leather tanning process, the leather on this recliner remains pristine, even with playful pets around. This added durability ensures that your chair will continue to look and feel as luxurious as the day you bought it.

Whether you have a dog that loves to jump on the couch or a cat that enjoys lounging with you, the Tuscany Ultimate Heat & Ventilation Recliner will withstand everyday wear and tear, providing years of enjoyment.

Ergonomic Support for Maximum Comfort

Designed with ergonomics in mind, the Tuscany Ultimate Heat & Ventilation Recliner features perforated lumbar support, which provides extra support for your lower back while maintaining comfort throughout extended sitting periods. The high-resiliency foam used in the cushion is specially designed to contour to your body, ensuring that every inch of the recliner fits you perfectly. This unique foam technology mimics the feel of a plush mattress, providing a level of comfort that is ideal for long movie marathons or game nights.

The power headrest also offers customizable support, allowing you to adjust the angle of your headrest to achieve the most comfortable viewing position. Whether you’re sitting upright or fully reclined, the Tuscany Ultimate Heat & Ventilation Recliner ensures that you have the best support for your neck and head, minimizing any strain.

Wall-Hugging Design for Maximum Space Efficiency

The Tuscany Ultimate Heat & Ventilation Recliner is designed to save space, making it ideal for rooms with limited space. The wall-hugging recline mechanism allows you to fully recline without needing to move the chair away from the wall. This design maximizes the use of your home theater space, ensuring that you can enjoy the full comfort of the recliner without compromising on available room.

Luxury and Innovation Combined

With the Tuscany Ultimate Heat & Ventilation Recliner, Valencia Theater Seating continues its legacy of providing top-of-the-line luxury and innovation. Whether you’re a movie lover, a gamer, or someone who simply enjoys the finer things in life, this recliner offers the perfect blend of style, comfort, and cutting-edge technology. It is more than just a chair; it’s an experience.

 

Available Now

The Tuscany Ultimate Heat & Ventilation Recliner is now available for purchase through Valencia Theater Seating’s official website. To learn more about the product and place your order, visit us.valenciatheaterseating.com.

For any questions or inquiries regarding the Tuscany Ultimate Heat & Ventilation Recliner, please contact Valencia Theater Seating’s customer support team at sales@valenciatheaterseating.com.

About Valencia Theater Seating

Valencia Theater Seating USA

Valencia Theater Seating is North America’s premier specialist in luxury home theater seating. Committed to excellence, every Valencia chair is meticulously designed to provide unparalleled support, from the legs to the head, with strategically placed ergonomic foam ensuring complete comfort. Built with longevity in mind, our chairs feature solid wood construction, durable metal reclining mechanisms, and high-quality foam that maintain their shape and comfort for decades.

Blending the finest craftsmanship, cutting-edge technology, and timeless style, Valencia Theater Seating has earned its reputation as a trusted name in the home entertainment industry. Visit our Dallas showroom to explore our exclusive range of seating options, including the luxurious 20,000 Nappa semi-aniline leather. Browse leather samples to find the perfect finish to complement your style and elevate your home entertainment space.
 

Media Contact

Organization: Valencia Theater Seating

Contact
Person: Dave H

Website:

https://us.valenciatheaterseating.com

Email:

dave@valenciatheaterseating.com

Address:14460 Midway Rd

Address 2: TX 75244

City: Dallas

Country:United States

The post Valencia Theater Seating Announces the Launch of the Ultimate Tuscany Heat and Ventilation Recliner appeared first on
Grand Newswire.
It is provided by a third-party content
provider. Grand Newswire makes no
warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us